Publications & Resources

MLMIC’s Q2 financials show continued strength and stability for New York’s leading medical liability insurer. In a constantly changing insurance marketplace, it is reassuring to know that MLMIC is sound and ready to serve its policyholders.

Policyholders have reacted to the Berkshire Hathaway agreement with enthusiasm and questions that we receive are typically about the transaction’s timing, payout, next steps and notices.

MLMIC is pleased to announce that DFS approval of MLMIC’s 2017 rates means that base rates remain unchanged for all physician policyholders for July 1, 2017, to July 1, 2018. DFS also approved a number of specialty class changes and a small adjustment to how entity rates are calculated.

While there’s no getting around the intense emotions involved in being sued, a solid support system makes a big difference. This includes not only family, friends and colleagues but also skilled legal counsel.

We’re pleased to advise policyholders that the Berkshire Hathaway transaction is on track. As such, you can expect several major milestones to occur between now and the expected close of the transaction by year-end 2017.

MLMIC’s latest dividend is based on overall assets of $5.8 billion, a surplus of $1.9 billion and a net income of $100 million. These figures, available in the company’s Q3 statement, show the company’s overall financial condition remains sound.

We want you to be among the first to know our latest good news: MLMIC has entered into a definitive agreement to be acquired by National Indemnity Company, a subsidiary of Berkshire Hathaway.

MLMIC will not raise rates for physician policyholders this year. In addition, it announces credits for the 20% dividend and expands claims-free discount program.

MLMIC’s Board of Directors has approved a 20 percent dividend for all MLMIC policyholders.

Medscape data offers some perspective related to medical liability and malpractice litigation.